Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,80
KB0,17
PKN68,4468,471,17
Msft400,84400,920,44
Nokia3,3333,47554,20
IBM182,84182,890,69
Mercedes-Benz Group AG74,3174,320,07
PFE26,4726,481,83
22.04.2024 20:05:58
Indexy online
AD Index online
select
AD Index online
 

  • 22.04.2024 17:33:45
Novartis AG (NOVN.VX, Virt-x)
Poslední obchod Změna (%) Změna (CHF) Objem obchodů (CHF)
87,36 2,14 1,83 321 140 837
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 22.04.2024
Popis společnosti
Obecné informace
Název společnostiNovartis AG
TickerNOVN
Kmenové akcie:Ordinary Shares
RICNOVN.S
ISINCH0012005267
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 76 057
Akcie v oběhu k 31.12.20232 044 033 986
MěnaUSD
Kontaktní informace
UliceLichtstrasse 35
MěstoBASEL
PSČ4056
ZeměSwitzerland
Kontatní osoba 
Funkce kontaktní osoby 
Telefon41 613 241 111
Fax41613247826

Business Summary: Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Novartis AG revenues increased 8% to $46.66B. Net income before extraordinary items increased 42% to $8.57B. Revenues reflect United States segment increase of 13% to $17.96B, China segment increase of 11% to $3.27B. Net income benefited from Research & Development - Balancing value decrease of 8% to $8.6B (expense), Restructuring Charges decrease of 36% to $1.18B (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICSSurgical and Medical Instrument Manufacturing
NAICSOphthalmic Goods Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSOffices of Other Holding Companies
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Medicinal & Botanical Mfg
NAICS2007Surgical & Medical Instrument Mfg
NAICS2007Ophthalmic Goods Mfg
NAICS2007Research and Development in Biotechnology
NAICS2007Offices of Other Holding Companies
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Medicinal and Botanical Manufacturing
NAICS1997Surgical and Medical Instrument Manufacturing
NAICS1997Ophthalmic Goods Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Offices of Other Holding Companies
SICPharmaceutical Preparations
SICBiological Prod's Not Diagnostic
SICMedicinals And Botanicals
SICSurgical And Medical Instruments
SICOphthalmic Goods
SICCommercial Physical Research
SICHolding Companies, Nec



  • Poslední aktualizace: 22.04.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Member of the Executive CommitteeVasant Narasimhan4801.02.201801.02.2016
Chief Financial Officer, Member of the Executive CommitteeHarry Kirsch5901.05.201301.05.2013
Chief People and Organization Officer, Member of the Executive CommitteeRobert Kowalski5601.09.202101.09.2021
Chief Ethics, Risk and Compliance Officer, Member of the Executive CommitteeKlaus Moosmayer5601.12.201801.12.2018
President - Global Drug Development and Chief Medical Officer, Member of the Executive CommitteeShreeram Aradhye6216.05.202216.05.2022
President - Innovative Medicines US, Member of the Executive CommitteeVictor Bulto4601.05.202204.04.2022
Chief Strategy and Growth Officer, Member of the Executive CommitteeAaron Gal5818.07.202218.07.2022
Chief Legal Officer, Member of the Executive BoardKaren Hale5615.05.202115.05.2021
President - International, Member of the Executive BoardPatrick Horber5401.12.202301.12.2023
President - Operations, Member of the Executive CommitteeSteffen Lang5704.04.202201.01.2017